The earnings transcript for Merck & Co., Inc. reveals several key points that could influence the short-term stock performance:

### Positive Factors
- Merck reported solid first-quarter results, including growth in non-GAAP EPS and revenue from key products like SINGULAIR, COZAAR/HYZAAR, GARDASIL, JANUVIA, JANUMET, and ISENTRESS.
- The company maintained its full-year non-GAAP EPS guidance and slightly revised its GAAP EPS guidance upward.
- Strong international performance, particularly in Japan, Asia, and Europe, contributed significantly to the top line.
- Merck is making significant progress in its restructuring and cost-cutting efforts, which are expected to enhance efficiency and competitiveness.

### Negative Factors
- The loss of patent protection for FOSAMAX and lower-than-expected sales from the Merck/Schering-Plough joint venture, particularly for VYTORIN and ZETIA, due to the ENHANCE trial controversies, led to a $700 million reduction in equity income guidance.
- Despite efforts to address the ENHANCE trial impact, there was a notable decline in VYTORIN and ZETIA sales in the US, which could continue to affect short-term performance.

### Neutral Factors
- The tax rate guidance was revised due to the recognition of foreign tax credits, which is a one-time event and does not reflect ongoing operational performance.
- Share repurchase activities were significant in the first quarter, but this is more about timing and capital allocation rather than a direct indicator of future stock performance.

### Conclusion
Given the mixed signals, the short-term impact on Merck's stock is likely to be neutral to slightly negative. While the company's solid financial performance, strong product portfolio, and ongoing efficiency improvements are positives, the significant decline in VYTORIN and ZETIA sales and the associated reduction in equity income guidance could weigh on investor sentiment in the short term.

**Rating: 0**